I ncreasing health care costs have long been cited as a major concern in the United States and other high-income nations, with spending in the United States exceeding that of other nations. 1 Conventional wisdom has pointed to a fee-forservice system incentivizing higher use of health care resources and driving higher health care spending in the United States. 2 However, a study in JAMA 1(p1024) has implicated prices of "labor and goods, including pharmaceuticals and devices, and administrative costs" as the main drivers of higher US health care spending when compared with other high-income nations. From 2005 to 2014, ophthalmologic medications accounted for the largest annual spending growth but lagged behind oncologic, urologic, primary care, and rheumatologic medications for overall US Medicare Part B drug spending. 3 Australia is another high-income nation with parallel practice patterns to the United States in that most medical professionals are self-employed in private practice and compensated by fee-for-service, with some movement toward group practice and alternative payment models. 4 In addition, Australia has been noted to have a similar overall burden of disease and demographics compared with the United States. 1, 5, 6 Unlike the United States, however, the Australian governmentrun Pharmaceutical Benefits Scheme (PBS) provides most prescription drugs with a highly subsidized patient copayment.
7
Despite fee-for-service billing, Australia had the lowest health care spending among the 10 highest-income nations at 9.6% of its gross domestic product, whereas the United States spent 17.8% of its gross domestic product on health care according to the most recently available estimates from a 2018 study.
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In Australia, 3 of the 6 overall highest-cost medications to the PBS are used for ophthalmic disease: adalimumab (Humira; Abbvie, Inc), aflibercept (Eylea; Regeneron Pharmaceuticals), and ranibizumab (Lucentis; Genentech), which were the third, fifth, and sixth highest-cost medications, respectively, for the fiscal year 2016-2017. 8 Although adalimumab has a variety of indications and noninfectious uveitis has only been a recent addition, aflibercept and ranibizumab are exclusively used for ophthalmic indications. [9] [10] [11] Because prices have been identified as the main driver of higher US health care spending, we aimed to examine how the prices of aflibercept, ranibizumab, and adalimumab changed from 2013 to 2017 in the United States and Australia. Both countries have fee-for-service billing and a high cost of ophthalmic medications but a large disparity in overall health care costs. Our study aims to assess how medication prices have changed for aflibercept, ranibizumab, and adalimumab in each country to provide further information on how ophthalmic care may contribute to overall rising health care costs.
Methods

Data Collection
Data for this price comparison came from publicly available information, and this study did not involve any human participants or related data. Therefore, institutional review board approval and informed consent were waived.
Prices in the United States were collected from the publicly available Medicare Part B Drug and Biological Average Sales Price Index quarterly payment files. 12 The prices in these files represent the dollar amounts used to pay for Part B-covered drugs for a given quarter of a given year and are calculated based on manufacturer reporting of the mean sales price. The data were collected and analyzed from March 28 to May 4, 2018. For aflibercept, ranibizumab, and adalimumab, we collected prices from the July files from 2013 to 2017 with the exception of the 2017 price for adalimumab, which came from the January file because no price was listed for adalimumab in the July file. The prices were based on a dosage of 0.5 mg of ranibizumab, 2 mg of aflibercept, and 40 mg of adalimumab. We must note that the 0.3-mg dosage of ranibizumab is unique to the United States and was not included in this analysis because it is not used abroad, prohibiting an equivalent international price comparison. Australian prices in Australian dollars were collected from the government PBS Expenditure and Prescription report for the years 2013 to 2017, each of which cite the price in July of that year. 13 Prices for aflibercept, ranibizumab, and adalimumab were collected from the table listing drugs sorted by highest government cost. Per the PBS report, these prices were calculated by dividing the total cost of the drug (ie, the cost to the patient plus the cost to the government) by the total prescription volume for a given year.
Statistical Analysis
In accordance with guidelines set by the International Society for Pharmacoeconomics and Outcomes Research Task Force on Good Research Practices and prior published studies, [14] [15] [16] [17] all prices used in this study were adjusted for inflation using consumer price indices and converted into US dollars based on annual exchange rates obtained from the X-rates currency calculator. 13 To compare how the costs and the rate of in- The estimated percentage change per year for ranibizumab when accounting for inflation was −2.6% (95% CI, −3.9% to −1.3%) in the United States compared with −18.5% (95% CI, −29.3% to −7.8%) in Australia (P = .003). The difference in price of ranibizumab between the 2 nations was $55 less in the United States in 2013 and annually rising to $933 more in the United States in 2017. Compared with Australia, the percentage change in price per year was 15.9% greater in the United States during this period (95% CI, 7.6%-24.2%; P = .003).
The estimated percentage change for aflibercept per year was −1.5% (95% CI, −2.2% to −0.7%) in the United States compared with −16.9% (95% CI, −25.1% to −8.6%) in Australia (P = .001). The difference in aflibercept price was $44 more expensive in the United States in 2013 and increased to $960 more expensive in the United States in 2017 (P = .001) (Table and Figure, C) . The percentage change in price per year was 15.4% greater in the United States compared with Australia during this period (95% CI, 9.1%-21.8%; P = .001).
Discussion
The price of adalimumab, ranibizumab, and aflibercept decreased during the past 5 years in Australia compared with the United States. The prices of ranibizumab and aflibercept remained relatively stable throughout the United States from 2013 to 2017 but declined in Australia. Although the price of adalimumab was initially higher in Australia compared with the United States, an inverse price change occurred from 2013 to 2017 with a progressively increasing price in the United States and a progressively decreasing price in Australia. The increase in adalimumab price in the United States may coincide with its 2014 approval by the US Food and Drug Administra- tion for noninfectious uveitis, leading to the US inflationadjusted price in 2014 of $1290 to increase to $1734 in 2016. However, further study is needed to assess this change in price.
Strengths and Limitations
The strengths of our study are that we used published citable prices from the largest payers for medications in the 
Conclusions
Ranibizumab, adalimumab, and aflibercept each have the potential to provide tremendous benefit to patients globally. The prices of adalimumab, ranibizumab, and aflibercept significantly decreased during the past 5 years in Australia compared with the United States. These data, however, do not indicate why these differences are noted or what actions might affect future pricing in either country. prices were observed in Australia, whereas US prices increased or remained relatively stable for adalimumab, ranibizumab, and aflibercept. All prices are expressed in 2017 US dollars.
